-
HETEROGENEOUS RESPONSES TO BRAZIL’S PHARMACEUTICAL PRICE CAP REGULATION: EVIDENCE FROM PRIVATE INSURANCES AND THE UNIFIED HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A MULTI-AGENT "DEEP" AI SYSTEM FOR HEOR EVIDENCE AND INTELLIGENCE GENERATION
Mar 18, 2026, 21:38 PM -
A SYSTEMATIC REVIEW OF FINDINGS AND METHODS IN ECONOMIC EVALUATIONS OF DYADIC HEALTHCARE INTERVENTIONS
Mar 18, 2026, 21:38 PM -
HUMANISTIC BURDEN IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) USING PATIENT-REPORTED OUTCOME MEASURES (PROMS)
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COST BURDEN IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY IN ADULT PATIENTS WITH ACUTE RESPIRATORY INFECTION IN A COLOMBIAN REFERRAL HOSPITAL
Mar 18, 2026, 21:38 PM -
MODELLING HEALTH SYSTEM CAPACITY AND MEASUREMENT DISPERSION TO EXPLAIN CROSS-NATIONAL VARIATION IN EQVT UTILITY VALUES
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING (CGM) FOR ADULTS WITH TYPE 1 DIABETES IN IRELAND
Mar 18, 2026, 21:38 PM -
BREAST CANCER PATTERNS AND TREATMENT ACCESS IN DENMARK: IDENTIFYING OPPORTUNITIES FOR DECENTRALIZED CARE IN BREAST CANCER CARE (HEATMAP-ONKO-BREAST)
Mar 18, 2026, 21:38 PM -
REAL-WORLD DIAGNOSTIC DELAY, TREATMENT ACCESS, AND HEALTH SYSTEM BURDEN IN PRIMARY IMMUNODEFICIENCY/INBORN ERRORS OF IMMUNITY: EVIDENCE FROM THE UNITED STATES AND EX-US SETTINGS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Mar 18, 2026, 21:38 PM -
TEMPORAL TRENDS AND PREDICTORS OF FIRST-LINE CHEMOTHERAPY AMONG OLDER WOMEN DIAGNOSED WITH TRIPLE-NEGATIVE BREAST CANCER IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
IMPACT OF EMERGENCY DEPARTMENT (ED) INVOLVEMENT AT CANCER DIAGNOSIS ON HEALTHCARE COSTS (HCC) ACROSS CANCER TYPES IN THE MEDICARE POPULATION
Mar 18, 2026, 21:38 PM -
WHEN THERAPIES ARE TARGETED BUT METHODS ARE GUESSING: CLOSING THE GAP IN PRECISION ONCOLOGY EVALUATION
Mar 18, 2026, 21:38 PM -
INCLUSIVE HEALTH RESEARCH IN THE PALM OF YOUR HAND: THE EVIDATION EVERYONE REGISTRY
Mar 18, 2026, 21:38 PM -
STREAMLINING KIDNEY TRANSPLANT COORDINATION THROUGH PROCESS MAPPING: IMPROVING TIMELINESS, REGULATORY COMPLIANCE, AND ORGAN UTILISATION IN A TERTIARY HOSPITAL
Mar 18, 2026, 21:38 PM -
ACCESS TO CARE, QUALITY OF LIFE AND MENTAL HEALTH SERVICE UTILIZATION AMONG US ADULTS WITH DEPRESSION
Mar 18, 2026, 21:38 PM -
TRENDS IN SPECIALTY DRUG COVERAGE POLICY COMPLEXITY AMONG US COMMERCIAL HEALTH PLANS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES
Mar 18, 2026, 21:38 PM -
REAL-WORLD EFFICACY OF AUMOLERTINIB IN PATIENTS WITH ADVANCED EGFR T790M-POSITIVE NON-SMALL CELL LUNG CANCER: A MULTICENTRE RETROSPECTIVE COHORT STUDY IN JIANGSU PROVINCE, CHINA
Mar 18, 2026, 21:38 PM
